hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06343857, orgStudyIdInfo id: CE-AVEC 878/2022/Oss/AOUFe, briefTitle: Joint Self-Assessment Forms for Knee, Ankle and Shoulder, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University Hospital of Ferrara, class: OTHER, descriptionModule briefSummary: The present study represents the pilot phase of the project aimed at developing anatomical site-specific self-assessment questionnaires (shoulder, knee and ankle) that can advise the subject of the need for an orthopaedic specialist examination.The pilot phase of the project involves the collection of data from questionnaires in a population of subjects who have requested an orthopaedic consultation for the anatomical site covered by the questionnaire. Each questionnaire consists of questions designed to collect information about the patient's subjective condition.The data collected from the questionnaires will be used to evaluate the statistical significance (p value) of each question in the questionnaire in relation to the outcome of the orthopaedic specialist visit. Through a multivariate logistic analysis of the answers given by the subject, it will be possible to 'weight' each answer to obtain a final value that gives an indication of an orthopaedic specialist visit., conditionsModule conditions: Osteoarthritis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: self-assessment questionnaire, outcomesModule primaryOutcomes measure: Observation of the distribution of questionnaire responses for each anatomical site., secondaryOutcomes measure: Therapeutic indication of the orthopaedic specialist for each subject participating in the study, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Istituto Ortopedico Rizzoli, Clinica Ortopedica e Traumatologica II, city: Bologna, state: BO, country: Italy, geoPoint lat: 44.49381, lon: 11.33875, locations facility: Unità Operativa di Chirurgia della Spalla I.R.C.C.S. Ospedale Galeazzi-Sant'Ambrogio, city: Milan, state: MI, country: Italy, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06343831, orgStudyIdInfo id: IRB23-1646, briefTitle: Quantitative Assessment of Autologous Fat Transfer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University of Chicago, class: OTHER, collaborators name: National Institutes of Health (NIH), collaborators name: University of Houston, descriptionModule briefSummary: This is a single-arm, prospective pilot study that will objectively assess outcomes in patients electively undergoing Autologous Fat Transfer (AFT) for breast or chest wall reconstruction. Patients planning to undergo autologous fat transfer for breast or chest wall reconstruction will be enrolled prospectively. Participants will undergo standard photographs (2-D imaging) of their chest wall and torso, including the breasts, and complete a validated questionnaire (BREAST-QTM) to evaluate patient satisfaction, and quality of life, all standard of care. The 3D photographs, Magnetic resonance imaging (MRI), and Ultrasound (US) are routinely used in practice but will be performed for research purposes in this study. All imaging procedures and questionnaires will be obtained at baseline and follow-up visits 3-6., conditionsModule conditions: Autologous Fat Grafting, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Patients planning to undergo autologous fat transfer for breast or chest wall reconstruction will be enrolled prospectively. Participants will undergo standard photographs (2-D imaging) of their chest wall and torso, including the breasts, and complete a validated questionnaire (BREAST-QTM) to evaluate patient satisfaction, and quality of life, all standard of care. The 3D photographs, MRI, and US are routinely used in practice but will be performed for research purposes in this study., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: 2-Dimensional (2-D) Photographs (Visit 1/ Follow up Visit 3-6), interventions name: 3-Dimensional (3-D) Photographs (Visit 1- 6), interventions name: Ultrasound Soft Tissue Assessment (Visit 1/ Follow up Visit 4-6), interventions name: Magnetic Resonance Imaging Volume Assessment (Visit 1/ Follow up Visit 4-6), interventions name: BREAST-QTM questionnaire (Visit 1/ Follow up Visit 4-6), outcomesModule primaryOutcomes measure: Change from baseline in breast/chest wall following autologous fat grafting, measured by imaging., secondaryOutcomes measure: Change from baseline in quality of life as measured by the BREAST-QTM survey., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06343792, orgStudyIdInfo id: RLS-0071-203, briefTitle: Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease, acronym: AURORA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: ReAlta Life Sciences, Inc., class: INDUSTRY, descriptionModule briefSummary: This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory., conditionsModule conditions: Steroid Refractory GVHD, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: RLS-0071, outcomesModule primaryOutcomes measure: Number of participants with treatment-related adverse events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs), primaryOutcomes measure: Overall Response Rate (ORR) of RLS-0071, secondaryOutcomes measure: Incidence of refractoriness (to RLS-0071 +/- ruxolitinib), secondaryOutcomes measure: Overall corticosteroid use, secondaryOutcomes measure: Initiation of additional or alternative treatment(s) for aGvHD (including an increase in steroid dose to >2 mg/kg methylprednisolone equivalent), secondaryOutcomes measure: Change or shift in Stage for lower GI aGvHD, liver aGvHD, skin aGvHD, or upper GI aGvHD from baseline based on MAGIC Criteria, secondaryOutcomes measure: Attainment of Stage 0 or 1 lower GI aGvHD, liver aGvHD, skin aGvHD, or upper GI aGvHD, secondaryOutcomes measure: Change or shift in overall Grade of aGvHD, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Non-relapse mortality, secondaryOutcomes measure: Duration of hospital stay, eligibilityModule sex: ALL, minimumAge: 12 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06343766, orgStudyIdInfo id: RECO6U/24-2022, briefTitle: Polymorphisms in ENAM, AMBN, and KLK4 Contribute to DCS., statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-06, primaryCompletionDateStruct date: 2023-11-05, completionDateStruct date: 2023-11-05, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Amina Fouad Farag, class: OTHER, descriptionModule briefSummary: A Cross-Sectional Study aims to shed light on potential genetic determinants influencing dental caries susceptibility within this demographic and significantly understanding of genetic factors associated with dental caries, particularly within the context of the Egyptian population, providing valuable insights into the genetic aspects of oral health. The research methodology involved a comprehensive examination of these polymorphic loci ENAM, AMBN, TUFT1 and KLK4 and their prevalence, employing rigorous statistical analyses to establish potential correlations between these genetic variants and susceptibility to dental caries., conditionsModule conditions: Dental Caries Secondary to Polymorphisms, conditions: Polymorphisms in Enamel Encoding Genes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 204, type: ACTUAL, armsInterventionsModule interventions name: DNA collation and genotyping, outcomesModule primaryOutcomes measure: Polymorphisms in genes associated with enamel formation and mineralization and dental caries susceptibility., eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 22 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry, October 6 University, city: Giza, zip: 12511, country: Egypt, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06343753, orgStudyIdInfo id: FMASU MD46/2024, briefTitle: Quality of Recovery After Laparoscopic Cholecystectomy Comparing Opioid Free Analgesia Versus Opioid Free Anesthesia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-10-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: The aim of this study is to compare the quality of recovery from general anesthesia and surgery using the quality of recovery 15 item scale (QoR-15) for participant's receiving opioid-Sparing anesthesia with those receiving standard opioid-containing anesthesia in Patients undergoing a scheduled laparoscopic cholecystectomy., conditionsModule conditions: Quality of Recovery, conditions: Pain, Postoperative, conditions: Elective Laparoscopic Cholecystectomy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Opioid free analgesia, interventions name: Opioid based Anesthesia, outcomesModule primaryOutcomes measure: Quality of recovery, secondaryOutcomes measure: Post operative pain, secondaryOutcomes measure: Postoperative Hypoxia, secondaryOutcomes measure: Postoperative nausea and vomiting, secondaryOutcomes measure: Postoperative bradycardia, secondaryOutcomes measure: Postoperative hypotension, secondaryOutcomes measure: Postoperative hypertension, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ain Shams University, city: Cairo, country: Egypt, contacts name: Ahmed El-ghanam, role: CONTACT, phone: 201116171706, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06343740, orgStudyIdInfo id: PSY-2324-S-0136, briefTitle: First Evaluation of COMET-Y, acronym: COMET-Y, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Accare, class: OTHER, descriptionModule briefSummary: The goal of this pilot study is to evaluate COMET-Y in 22 adolescents (11-18 years) with various mental health problems and low self-esteem. The main questions is: Does COMET-Y, parallel to care as usual (CAU), improve self-esteem?Before and after the training participants fill in questionnaires to measure self-esteem, mental health problems, resilience, quality of life, emotions and individual goals. Some of the outcomes are measured through diary methods. Youth and therapists will be assessed to evaluate feasibility and acceptability of the COMET-Y training., conditionsModule conditions: Self Esteem, conditions: Quality of Life, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This pilot study is a pre-post study., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 22, type: ESTIMATED, armsInterventionsModule interventions name: COMET-Y, outcomesModule primaryOutcomes measure: Self Esteem, secondaryOutcomes measure: Domain-specific Self Esteem, secondaryOutcomes measure: Mental Health Problems, secondaryOutcomes measure: Quality of life, secondaryOutcomes measure: Affect, secondaryOutcomes measure: Resilience, secondaryOutcomes measure: Ecological Momentary Assessments - Global self-esteem, secondaryOutcomes measure: Ecological Momentary Assesments - Goal Based Outcome (GBO) tool for young people, secondaryOutcomes measure: Ecological Momentary Assesments - Domain-specific self-esteem, eligibilityModule sex: ALL, minimumAge: 11 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06343727, orgStudyIdInfo id: HS25870 (H2023:026), briefTitle: A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-07-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Seven Oaks Hospital Chronic Disease Innovation Centre, class: NETWORK, collaborators name: University of Manitoba, collaborators name: Manitoba Egg Farmers, descriptionModule briefSummary: The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are:* To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible.* To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements.* To determine the effects of the egg white protein pudding on frailty measures, dietary intakes and analytes in the blood and urine. Participants will receive either the egg white pudding (experimental) or control (Ensure plus) at the end of their dialysis treatments 3-days per week for 12 weeks., conditionsModule conditions: Kidney Failure, conditions: Frailty, conditions: Kidney Disease, Chronic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This trial is an open-label randomized controlled parallel arm feasibility tria, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Egg white protein pudding, interventions name: : Ensure Plus, outcomesModule primaryOutcomes measure: Eligibility to randomization ratio, primaryOutcomes measure: Weekly recruitment rate, primaryOutcomes measure: Adherence to Egg pudding, secondaryOutcomes measure: Serum albumin, secondaryOutcomes measure: Hand grip strength, secondaryOutcomes measure: Change in gait speed, secondaryOutcomes measure: Five rep chair stand time, secondaryOutcomes measure: Tandem balance time, secondaryOutcomes measure: Serum bicarbonate, secondaryOutcomes measure: Calcium, secondaryOutcomes measure: Urine albumin, secondaryOutcomes measure: chloride, secondaryOutcomes measure: phosphorus, secondaryOutcomes measure: Potassium, secondaryOutcomes measure: Sodium, secondaryOutcomes measure: HbA1c, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06343714, orgStudyIdInfo id: FB1003-04-101, briefTitle: A Study of FB1003 in Healthy Subject, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-03, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: 4B Technologies Limited, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following administrations. For each participant, the study will last up to about 12 weeks for single ascending dose part, and 18 weeks for multiple ascending dose part, including screening., conditionsModule conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: FB1003, interventions name: Placebo, outcomesModule primaryOutcomes measure: The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with FB1003 or placebo., secondaryOutcomes measure: FB1003 serum concentrations over time, secondaryOutcomes measure: PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC0-∞) of FB1003, secondaryOutcomes measure: Presence of anti-FB1003 antibodies over time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06343701, orgStudyIdInfo id: BAİBÜ-SAT4, briefTitle: Investigation of Motor Imaging Skills in Children With Spastic Cerebral Palsy, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-18, primaryCompletionDateStruct date: 2024-05-05, completionDateStruct date: 2024-06-25, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Abant Izzet Baysal University, class: OTHER, descriptionModule briefSummary: The aim of this study was to investigate implicit and explicit motor imagery skills in children with spastic cerebral palsy and typically developing children. The main questions it aims to answer are:* There is a difference between the implicit motor imagery skills of children with bilateral and unilateral CP.* There is a difference between the explicit motor imagery skills of children with bilateral and unilateral CP.* There is a difference between the implicit motor imagery skills of children with cerebral palsy and typically developing children.* There is a difference between the explicit motor imagery skills of children with cerebral palsy and typically developing children., conditionsModule conditions: Cerebral Palsy, Spastic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Implicit motor imagery, interventions name: Explicit motor imagery, outcomesModule primaryOutcomes measure: Explicit motor imagery -1, secondaryOutcomes measure: Explicit motor imagery - 2, secondaryOutcomes measure: Explicit motor imagery - 3, secondaryOutcomes measure: Implicit motor imagery, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Kdz. Ereğli Gökkuşağı Özel Eğitim ve Rehabilitasyon Merkezi, status: RECRUITING, city: Zonguldak, state: Ereğli, zip: 67300, country: Turkey, contacts name: Seda AYAZ TAŞ, Phd, role: CONTACT, phone: 05495458040, email: seda.ayaztas@ibu.edu.tr, geoPoint lat: 41.45139, lon: 31.79305, locations facility: Bolu Abant İzzet Baysal University, status: RECRUITING, city: Bolu, state: Gölköy/ Bolu, zip: 14030, country: Turkey, contacts name: Seda Ayaz Taş, Phd, role: CONTACT, phone: 05495458040, email: seda.ayaztas@ibu.edu.tr, geoPoint lat: 40.73583, lon: 31.60611, locations facility: Düzce Gökkuşağı Özel Eğitim ve Rehabilitasyon Merkezi, status: RECRUITING, city: Düzce, state: Merkez, zip: 81100, country: Turkey, contacts name: Seda AYAZ TAŞ, Phd, role: CONTACT, phone: 05495458040, email: seda.ayaztas@ibu.edu.tr, geoPoint lat: 40.83889, lon: 31.16389, hasResults: False
protocolSection identificationModule nctId: NCT06343662, orgStudyIdInfo id: Meraki_Acquired Brain Injury, briefTitle: Group Music Therapy for Acquired Brain Injury, acronym: Meraki_ABI, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of Valencia, class: OTHER, descriptionModule briefSummary: The study aims to analyse the impact of music therapy-based treatment on the comfort and well-being of patients with acquired brain injury (ABI). To achieve this objective, it is proposed to validate and implement a music therapy-based assessment and treatment protocol. The protocol will be tested in a pilot sample to improve adaptation to the disease and promote integration with the usual health measures of patients with ABI. Implementing a group treatment programme based on music therapy applied to patients with ABI., conditionsModule conditions: Acquired Brain Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: MERAKI_ABI, outcomesModule primaryOutcomes measure: Change in Discomfort ( Baseline (3 Assessments), Pre- Post), secondaryOutcomes measure: Barthel Index, secondaryOutcomes measure: Pfeiffer Short Form Mental State Questionnaire, SPMSQ, secondaryOutcomes measure: Charlson Comorbidity Index (CCI),, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Dr. Moliner, status: RECRUITING, city: Serra, state: Valencia, country: Spain, contacts name: Miguel Fombuena, PhD, role: CONTACT, email: fombuena_mig@gva.es, contacts name: Selene Valero-Moreno, PhD, role: SUB_INVESTIGATOR, contacts name: Isabel Bellver Vercher, role: SUB_INVESTIGATOR, contacts name: Ana Alegre Soler, role: SUB_INVESTIGATOR, contacts name: José Jorge Botella Trellis, Dr., role: SUB_INVESTIGATOR, contacts name: Cristina Rocío Espejo Fernández, Dra., role: SUB_INVESTIGATOR, contacts name: María Carmen Badía Picazo, Dra., role: SUB_INVESTIGATOR, geoPoint lat: 39.68333, lon: -0.43333, hasResults: False